H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida
Moffitt Cancer Center & Research Institute (MCC) was statutorily established as a free-standing not-for-profit entity by the Florida Legislature in 1981 to serve as the state’s cancer center. The Moffitt Cancer Center hospital opened in 1986 on the campus of the University of South Florida in Tampa, which was followed by active research effort beginning in 1994. Recognized as one of the fastest growing cancer centers in the U.S., Moffitt achieved NCI cancer center designation four years later (1998), and ultimately was awarded the prestigious NCI comprehensive cancer center designation in 2001.
Moffitt is dedicated to a singular mission: to contribute to the prevention and cure of cancer and today is recognized as a leader in the discovery, translation, and delivery of personalized cancer care and prevention. More than 4,000 physicians, scientists, and staff work together daily to translate new findings to the most innovative and personalized approaches to cancer treatment and prevention available.
The Moffitt Research Institute includes a team of more than 160 faculty members investigating particular aspects of cancer as part of five thematic scientific programs: Molecular Oncology and Drug Discovery; Immunology; Experimental Therapeutics; Cancer Epidemiology; and Health Outcomes and Behavior. These programs are highly collaborative, translational and span across multiple disease-sites.
Each scientific program focuses their research around specific scientific aims, which together, provide Moffitt’s strong, multidimensional approach to defeating cancer:
- The Molecular Oncology and Drug Discovery Program focuses on signal transduction pathways involved in malignant transformation, gene regulation related to tumor cell proliferation and survival, and molecular targets for cancer drug design.
- The Immunology Program studies innate immunity and cancer, adaptive immunity and tumor bearers as well as novel immunotherapies to treat cancer.
- The Experimental Therapeutics Program focuses on cancer therapeutic responses through rapid translation between laboratory and clinic and the design of novel clinical trials.
- The Cancer Epidemiology Program seeks to identify inherited and acquired susceptibility biomarkers, and test new approaches to prevention and early detection of cancer.
- The Health Outcomes and Behavior Program studies health-related behaviors and cancer; cancer care practices; health-related quality of life for cancer patients; and the social, cultural, and behavioral determinants of cancer-related health disparities.
One of Moffitt’s unique contributions to cancer research is its Institutional Review Board (IRB) approved Total Cancer Care™ (TCC) study. This nationally recognized observational study includes patients from 18 health care sites across 10 states, who have volunteered to contribute their tumor and longitudinal data to a lifelong study to accelerate the development of personalized approaches to cancer treatment and prevention. Total Cancer Care integrates a patient-centric approach to: identify the needs of individual patients; Identify markers that would predict needs; identify molecular signatures for patients to better select treatment, including clinical trials; and raise the standard of care for all patients using an evidenced based approach to maximize benefits and reduce costs.
Education and training for the next generation of scientists is an integral part of Moffitt’s mission. The Center has numerous efforts focused on education and training that includes extramurally-funded grants for predoctoral students, postdoctoral fellows, and residents. In addition, there is a major institutional investment in Mentorship Programs for physician scientists and clinical investigators.
* This profile was provided by the Moffitt Cancer Center.